bluebird bio (BLUE) PT Lowered to $14 at RBC Capital

November 8, 2021 6:28 AM

RBC Capital analyst Luca Issi lowered the price target on bluebird bio (NASDAQ: BLUE) to $14.00 (from $26.00) while maintaining a Sector Perform rating.

No results found